EMEA-001501-PIP07-20

Key facts

Invented name
Dupixent
Active substance
dupilumab
Therapeutic area
Dermatology
Decision number
P/0153/2021
PIP number
EMEA-001501-PIP07-20
Pharmaceutical form(s)
Solution for injection (in pre-filled syringe)
Condition(s) / indication(s)
Treatment of chronic spontaneous urticaria
Route(s) of administration
Subcutaneous use
Contact for public enquiries
sanofi-aventis recherche & développement

Tel. +33 1697 45695
E-mail: contact-us@sanofi.com

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

Related content

How useful was this page?

Add your rating